Wire reports
AstraZeneca says it has applied for authorization to market in Europe a drug combining low-dose aspirin with its best-selling ulcer drug Nexium.
The pharmaceutical company said Friday that the product, called Axanum, is designed for heart patients who develop gastric disorders from taking low-dose aspirin by itself.
On Tuesday, AstraZeneca said the U.S. Food and Drug Administration has asked for more information about Axanum, delaying the company’s hopes of selling the product in America.
AstraZeneca partnered with Chapel Hill, N.C.-based (Nasdaq: POZN) for a pain reliver called Vimovo.
Vimovo provides patients with osteoarthritis proven pain relief with gastric ulcer risk reduction, according to AstraZeneca.
(Note: this story has been updated to correct the usage for Vimovo.)
Get the latest news alerts: at Twitter.
